Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...

Race Oncology (ASX:RAC) has started working with George Clinical under a work order (WO) agreement for its Phase 1 RAC-010 ...

(PDCs) demonstrate tumor-selective delivery and potent anticancer activityPreclinical data show robust efficacy as ...

Olive-derived drugs could eventually find a place in your medicine cabinet as HonorHealth researchers explore their potential ...

BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research ...

This review of the literature affirms the role of prehabilitation in systemic anticancer therapy, and highlights how oncology nurses can impact outcomes of cancer treatment.

Tucatinib inhibits the tyrosine kinase enzyme of the HER-2 gene. Mutations of tyrosine kinase in the HER-2 gene lead to ...

ALX Oncology is laying off 30% of its staff, mainly in preclinical research, to redirect money toward clinical trials, ...

These cancers are, however, quite sensitive to anticancer drugs such as poly (ADP-ribose) polymerase inhibitors (PARPi). When ...

Scientists discovered a way to block hepatitis B infection using an anticancer drug, offering hope for new treatments.

Allogene Therapeutics (NASDAQ:ALLO) stock received an upgrade from Citizens on Friday after the company's Q4 2024 results.